| 0.185 0.006 (3.58%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.25 | 1-year : | 0.3 |
| Resists | First : | 0.22 | Second : | 0.25 |
| Pivot price | 0.18  |
|||
| Supports | First : | 0.15 | Second : | 0.13 |
| MAs | MA(5) : | 0.17  |
MA(20) : | 0.2 |
| MA(100) : | 0.7 |
MA(250) : | 3.08 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 16.8 |
| RSI | RSI(14): 31.8 |
|||
| 52-week | High : | 9.6 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VNRX ] has closed above bottom band by 47.1%. Bollinger Bands are 86% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.19 - 0.19 | 0.19 - 0.19 |
| Low: | 0.16 - 0.16 | 0.16 - 0.16 |
| Close: | 0.18 - 0.18 | 0.18 - 0.19 |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Tue, 27 Oct 2026
VolitionRx Hooks up with Missionpharma - TradingView
Tue, 27 Oct 2026
VolitionRx signs letter of intent with Missionpharma By Investing.com - Investing.com India
Tue, 27 Oct 2026
VolitionRx Limited (VNRX) Signs LOI to Develop NETosis Lateral Flow Test - TradingView
Tue, 27 Oct 2026
An estimated 2.3 million newborns die yearly. VolitionRx and Missionpharma explore a finger-prick newborn sepsis test. - Stock Titan
Tue, 27 Oct 2026
VolitionRx prepays $500,000 on convertible note to Lind By Investing.com - Investing.com Nigeria
Tue, 27 Oct 2026
VolitionRx Limited (VNRX) Prepays $500K, Secures Conversion Waiver - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|